Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares Issued
Ratios

Summit Therapeutics (SMMT) Long-Term Debt Issuances: 2016-2022

Historic Long-Term Debt Issuances for Summit Therapeutics (SMMT) over the last 1 years, with Dec 2022 value amounting to $520.0 million.

  • Summit Therapeutics' Long-Term Debt Issuances was N/A to $520.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $655.0 million, marking a year-over-year change of. This contributed to the annual value of $545.0 million for FY2022, which is 395.45% up from last year.
  • Latest data reveals that Summit Therapeutics reported Long-Term Debt Issuances of $520.0 million as of Q4 2022, which was up 1,980.00% from $25.0 million recorded in Q1 2022.
  • Summit Therapeutics' Long-Term Debt Issuances' 5-year high stood at $520.0 million during Q4 2022, with a 5-year trough of -$4.5 million in Q2 2018.
  • Over the past 2 years, Summit Therapeutics' median Long-Term Debt Issuances value was $55.0 million (recorded in 2021), while the average stood at $163.8 million.
  • Per our database at Business Quant, Summit Therapeutics' Long-Term Debt Issuances skyrocketed by 40.93% in 2018 and then slumped by 54.55% in 2022.
  • Quarterly analysis of 3 years shows Summit Therapeutics' Long-Term Debt Issuances stood at -$4.5 million in 2018, then reached $55.0 million in 2021, then plummeted by 54.55% to $520.0 million in 2022.
  • Its last three reported values are $520.0 million in Q4 2022, $25.0 million for Q1 2022, and $55.0 million during Q2 2021.